New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Ratios over time FY24 to FY26

Returns on capital

ROIC was −195.2% in FY26, against a low of −336.1% in FY24.

ROIC
FY24FY25FY26
ROIC−336.1%−173.4%−195.2%

Debt

Net debt is 0.08× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
FY24FY25FY26
Debt / equity0.0×0.0×0.0×
Net debt / EBITDA0.4×0.8×0.1×

Per share, from FY24

Since FY24, per share: revenue has grown 9.74% a year; book value has fallen 67.4% a year.

RevenueBook value
FY24FY25FY26
Revenue1.0×2.2×1.2×
Book value1.0×0.3×0.1×
Jun '26 Jun '25 Jun '24
Piotroski F-Score
3 — —
Altman Z-Score
(6.65) (2.74) —
Altman Z″-Score (non-manufacturers)
(16.22) (5.54) (8.32)
P/FCF ratio
0.00 0.00 0.00
Beneish M-Score
(2.62) 55.66 —
P/Operating CF
0.00 0.00 0.00
P/B ratio
0.00 0.00 0.00
EV/Sales
0.00 0.00 0.00
EV/EBITDA
0.00 0.00 0.00
EV/FCF
0.03 0.00 0.00
Current Ratio
1.16 2.67 1.30
Net Debt/EBITDA
0.08 0.82 0.42
Debt/Equity
0.00 0.00 0.00
ROE
(180.13%) (108.66%) —
ROA
(79.84%) (48.10%) —
ROIC
(195.15%) (173.45%) (336.13%)
Return on Tangible Assets
(1,852.14%) (153.53%) (899.05%)
Average Days of Receivables
2,300.75 1,044.76 1,204.57
Free Cash Flow Yield
0.00% 0.00% 0.00%
Free Cash Flow per Share
(3.50) (3.14) (11.70)
Book value per Share
1.48 4.00 13.93
Free Cash Flow
(35.82) (21.79) (15.07)
EV/EBIT
0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 2, 2026